EP480 - Auditing antiplatelet and statin prescription around admission on an inpatient vascular surgical unit

Abstract Aims Antiplatelet and Statin management is crucial in ensuring optimal outcomes for patients after peripheral arterial interventions (Vitturi et al, 2023; National Institute for Health and Care Excellence, 2020). The aim of this study was to interrogate if the patients were being discharged on the correct drugs and dosages following hospitalisation. Methods We investigated antiplatelet and statin prescription around admission and matched this with documented management plan on an inpatient vascular unit. Ward rounds were done by registrars along with Foundation Year 1 doctors (FY1s). Newly graduated FY1s with no prior vascular training rotated through the unit every four months. In October 2022, FY1s were educated on existing guidelines and they then handed over verbally to new FY1s in December, when a template was implemented documenting ward rounds and discharge planning. Two sets of data collection were done in October 2022 and then January 2023. Results Of 24 patients discharged in October 2022, 17(71%) received a statin, 7 did not. 15 (63%) patients received their planned antiplatelets, 1 received a different regimen; 8 (33%) had no clear plan outlined. Of 25 patients discharged in January, 15 (60%) received a statin; 10 were discharged without, but only 1 had a documented plan for this. 16 (64%) patients received antiplatelets as planned; 9 (36%) had no clearly documented plan. Conclusions Established guidelines recommend statin and antiplatelet treatment in Peripheral arterial disease. A clear plan should be outlined at discharge, with tools to ensure this particularly when working with juniors without prior experience. Of note, the documentation template developed was not used consistently.